Exploratory Prognostic Biomarkers of Complement-Mediated Thrombotic Microangiopathy (CM-TMA) in Adults with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of a Phase III Study of Ravulizumab

BACKGROUND: Clinically validated biomarkers for monitoring of patients with complement-mediated thrombotic microangiopathy (CM-TMA) including atypical hemolytic uremic syndrome (aHUS) are unavailable. Improved characterization of biomarkers in patients with aHUS may inform treatment and monitoring f...

Descripción completa

Detalles Bibliográficos
Autores principales: Cammett, Tobin J., Garlo, Katherine, Millman, Ellen E., Rice, Kara, Toste, Catherine M., Faas, Susan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813049/
https://www.ncbi.nlm.nih.gov/pubmed/36329366
http://dx.doi.org/10.1007/s40291-022-00620-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813049/
https://www.ncbi.nlm.nih.gov/pubmed/36329366
http://dx.doi.org/10.1007/s40291-022-00620-3

Ejemplares similares